BioXcel Therapeutics (NASDAQ:BTAI) Stock Rating Reaffirmed by HC Wainwright

BioXcel Therapeutics (NASDAQ:BTAI)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a note issued to investors on Tuesday, Benzinga reports. They presently have a $10.00 price objective on the stock. HC Wainwright’s price objective suggests a potential upside of 269.00% from the stock’s previous close.

A number of other equities analysts also recently commented on the company. UBS Group restated a “neutral” rating and issued a $4.00 price objective (down from $9.00) on shares of BioXcel Therapeutics in a report on Wednesday, February 21st. Canaccord Genuity Group dropped their target price on BioXcel Therapeutics from $18.00 to $7.00 and set a “buy” rating on the stock in a report on Thursday, March 14th. Finally, Bank of America dropped their target price on BioXcel Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a report on Wednesday, March 13th. Four equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $16.71.

BioXcel Therapeutics Stock Down 8.8 %

BTAI opened at $2.71 on Tuesday. The firm has a market cap of $100.35 million, a P/E ratio of -0.44 and a beta of 0.40. BioXcel Therapeutics has a 52 week low of $1.91 and a 52 week high of $29.56. The business’s fifty day simple moving average is $2.93 and its 200 day simple moving average is $3.19.

BioXcel Therapeutics (NASDAQ:BTAI) last released its earnings results on Tuesday, March 12th. The company reported ($0.76) earnings per share for the quarter, topping the consensus estimate of ($0.98) by $0.22. BioXcel Therapeutics had a negative return on equity of 890.63% and a negative net margin of 12,974.86%. The firm had revenue of $0.38 million for the quarter, compared to the consensus estimate of $1.17 million. As a group, equities analysts expect that BioXcel Therapeutics will post -2.46 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Apollon Wealth Management LLC bought a new stake in BioXcel Therapeutics during the 4th quarter valued at $31,000. Truist Financial Corp purchased a new position in shares of BioXcel Therapeutics during the fourth quarter valued at $32,000. Tower Research Capital LLC TRC grew its stake in BioXcel Therapeutics by 239.2% in the fourth quarter. Tower Research Capital LLC TRC now owns 13,832 shares of the company’s stock valued at $41,000 after purchasing an additional 9,754 shares in the last quarter. Hennion & Walsh Asset Management Inc. grew its stake in BioXcel Therapeutics by 89.5% in the third quarter. Hennion & Walsh Asset Management Inc. now owns 33,940 shares of the company’s stock valued at $86,000 after purchasing an additional 16,032 shares in the last quarter. Finally, Virtu Financial LLC acquired a new stake in shares of BioXcel Therapeutics in the fourth quarter worth about $176,000. Institutional investors and hedge funds own 30.68% of the company’s stock.

BioXcel Therapeutics Company Profile

BioXcel Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices.